Conjugate Vaccine Market Research Report by Type (Monovalent and Multivalent), by Indication (Diphtheria and Pertussis, Influenza, and Meningococcal), by Pathogen Type, by End User, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Gl

Conjugate Vaccine Market Research Report by Type (Monovalent and Multivalent), by Indication (Diphtheria and Pertussis, Influenza, and Meningococcal), by Pathogen Type, by End User, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

The Global Conjugate Vaccine Market size was estimated at USD 29.40 billion in 2020 and expected to reach USD 32.43 billion in 2021, at a CAGR 10.62% to reach USD 53.89 billion by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.


Market Segmentation & Coverage:

This research report categorizes the Conjugate Vaccine to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the market was studied across Monovalent and Multivalent.

Based on Indication, the market was studied across Diphtheria and Pertussis, Influenza, Meningococcal, and Pneumococcal.

Based on Pathogen Type, the market was studied across Bacterial Conjugate Vaccine, Combination Conjugate Vaccine, and Viral Conjugate Vaccine.

Based on End User, the market was studied across Adults Conjugate Vaccine and Pediatrics Conjugate Vaccine.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Conjugate Vaccine Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Conjugate Vaccine Market, including Bharat Biotech, Biological E. Ltd, CSL Limited, GlaxoSmithKline, plc., Merck and Company, Novartis AG, Nuron Biotech Inc., Pfizer, Inc., Sanofi Pasteur, and Serum Institute of India.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Conjugate Vaccine Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Conjugate Vaccine Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Conjugate Vaccine Market?
4. What is the competitive strategic window for opportunities in the Global Conjugate Vaccine Market?
5. What are the technology trends and regulatory frameworks in the Global Conjugate Vaccine Market?
6. What is the market share of the leading vendors in the Global Conjugate Vaccine Market?
7. What modes and strategic moves are considered suitable for entering the Global Conjugate Vaccine Market?


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
3.1. Introduction
4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.2.1. Increasing prevalence of infectious diseases
5.2.2. Rising adoption of cancer therapeutic vaccines
5.2.3. Rising number programs to promote vaccination by WHO
5.3. Restraints
5.3.1. Low accessibility to vaccines in remote areas
5.4. Opportunities
5.4.1. Government initiatives for infectious diseases
5.4.2. Advancement in technology of emergin pathogens
5.5. Challenges
5.5.1. Complexity of production procedure of conjugate vaccine
6. Conjugate Vaccine Market, by Type
6.1. Introduction
6.2. Monovalent
6.3. Multivalent
7. Conjugate Vaccine Market, by Indication
7.1. Introduction
7.2. Diphtheria and Pertussis
7.3. Influenza
7.4. Meningococcal
7.5. Pneumococcal
8. Conjugate Vaccine Market, by Pathogen Type
8.1. Introduction
8.2. Bacterial Conjugate Vaccine
8.3. Combination Conjugate Vaccine
8.4. Viral Conjugate Vaccine
9. Conjugate Vaccine Market, by End User
9.1. Introduction
9.2. Adults Conjugate Vaccine
9.3. Pediatrics Conjugate Vaccine
10. Americas Conjugate Vaccine Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Conjugate Vaccine Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
12. Europe, Middle East & Africa Conjugate Vaccine Market
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Bharat Biotech
14.2. Biological E. Ltd
14.3. CSL Limited
14.4. GlaxoSmithKline, plc.
14.5. Merck and Company
14.6. Novartis AG
14.7. Nuron Biotech Inc.
14.8. Pfizer, Inc.
14.9. Sanofi Pasteur
14.10. Serum Institute of India
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL CONJUGATE VACCINE MARKET SIZE, 2020 VS 2026 (USD BILLION)
FIGURE 2. GLOBAL CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 3. GLOBAL CONJUGATE VACCINE MARKET: MARKET DYNAMICS
FIGURE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
FIGURE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2020 VS 2026 (USD BILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2026
FIGURE 7. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MONOVALENT, 2018-2026 (USD BILLION)
FIGURE 8. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MONOVALENT, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 9. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MULTIVALENT, 2018-2026 (USD BILLION)
FIGURE 10. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MULTIVALENT, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 11. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2020 VS 2026 (%)
FIGURE 12. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2020 VS 2026 (USD BILLION)
FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2026
FIGURE 14. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY DIPHTHERIA AND PERTUSSIS, 2018-2026 (USD BILLION)
FIGURE 15. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY DIPHTHERIA AND PERTUSSIS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 16. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INFLUENZA, 2018-2026 (USD BILLION)
FIGURE 17. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INFLUENZA, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 18. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MENINGOCOCCAL, 2018-2026 (USD BILLION)
FIGURE 19. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 20. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PNEUMOCOCCAL, 2018-2026 (USD BILLION)
FIGURE 21. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 22. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2020 VS 2026 (%)
FIGURE 23. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2020 VS 2026 (USD BILLION)
FIGURE 24. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2026
FIGURE 25. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY BACTERIAL CONJUGATE VACCINE, 2018-2026 (USD BILLION)
FIGURE 26. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY BACTERIAL CONJUGATE VACCINE, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 27. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COMBINATION CONJUGATE VACCINE, 2018-2026 (USD BILLION)
FIGURE 28. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COMBINATION CONJUGATE VACCINE, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 29. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY VIRAL CONJUGATE VACCINE, 2018-2026 (USD BILLION)
FIGURE 30. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY VIRAL CONJUGATE VACCINE, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 31. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2020 VS 2026 (%)
FIGURE 32. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2020 VS 2026 (USD BILLION)
FIGURE 33. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2026
FIGURE 34. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY ADULTS CONJUGATE VACCINE, 2018-2026 (USD BILLION)
FIGURE 35. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY ADULTS CONJUGATE VACCINE, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 36. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PEDIATRICS CONJUGATE VACCINE, 2018-2026 (USD BILLION)
FIGURE 37. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PEDIATRICS CONJUGATE VACCINE, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 38. AMERICAS CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 39. ARGENTINA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 40. BRAZIL CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 41. CANADA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 42. MEXICO CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 43. UNITED STATES CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 44. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 45. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 46. CHINA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 47. INDIA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 48. INDONESIA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 49. JAPAN CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 50. MALAYSIA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 51. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 52. SINGAPORE CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 53. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 54. TAIWAN CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 55. THAILAND CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 56. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 57. FRANCE CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 58. GERMANY CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 59. ITALY CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 60. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 61. QATAR CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 62. RUSSIA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 63. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 64. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 65. SPAIN CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 66. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 67. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 68. GLOBAL CONJUGATE VACCINE MARKET: FPNV POSITIONING MATRIX
FIGURE 69. GLOBAL CONJUGATE VACCINE MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 70. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL CONJUGATE VACCINE MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL CONJUGATE VACCINE MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MONOVALENT, BY REGION, 2018-2026 (USD BILLION)
TABLE 6. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MULTIVALENT, BY REGION, 2018-2026 (USD BILLION)
TABLE 7. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2026 (USD BILLION)
TABLE 8. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY DIPHTHERIA AND PERTUSSIS, BY REGION, 2018-2026 (USD BILLION)
TABLE 9. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2026 (USD BILLION)
TABLE 10. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2026 (USD BILLION)
TABLE 11. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2018-2026 (USD BILLION)
TABLE 12. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2026 (USD BILLION)
TABLE 13. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY BACTERIAL CONJUGATE VACCINE, BY REGION, 2018-2026 (USD BILLION)
TABLE 14. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COMBINATION CONJUGATE VACCINE, BY REGION, 2018-2026 (USD BILLION)
TABLE 15. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY VIRAL CONJUGATE VACCINE, BY REGION, 2018-2026 (USD BILLION)
TABLE 16. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 17. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY ADULTS CONJUGATE VACCINE, BY REGION, 2018-2026 (USD BILLION)
TABLE 18. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PEDIATRICS CONJUGATE VACCINE, BY REGION, 2018-2026 (USD BILLION)
TABLE 19. AMERICAS CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 20. ARGENTINA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 21. BRAZIL CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 22. CANADA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 23. MEXICO CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 24. UNITED STATES CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 25. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 26. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 27. CHINA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 28. INDIA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 29. INDONESIA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 30. JAPAN CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 31. MALAYSIA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 32. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 33. SINGAPORE CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 34. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 35. TAIWAN CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 36. THAILAND CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 37. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 38. FRANCE CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 39. GERMANY CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 40. ITALY CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 41. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 42. QATAR CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 43. RUSSIA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 44. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 45. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 46. SPAIN CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 47. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 48. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 49. GLOBAL CONJUGATE VACCINE MARKET: SCORES
TABLE 50. GLOBAL CONJUGATE VACCINE MARKET: BUSINESS STRATEGY
TABLE 51. GLOBAL CONJUGATE VACCINE MARKET: PRODUCT SATISFACTION
TABLE 52. GLOBAL CONJUGATE VACCINE MARKET: RANKING
TABLE 53. GLOBAL CONJUGATE VACCINE MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 54. GLOBAL CONJUGATE VACCINE MARKET: MERGER & ACQUISITION
TABLE 55. GLOBAL CONJUGATE VACCINE MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 56. GLOBAL CONJUGATE VACCINE MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 57. GLOBAL CONJUGATE VACCINE MARKET: INVESTMENT & FUNDING
TABLE 58. GLOBAL CONJUGATE VACCINE MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 59. GLOBAL CONJUGATE VACCINE MARKET: LICENSE & PRICING

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook